Laboratorio Chile S.A. makes branded, generic, and OTC drugs, including treatments for respiratory and infectious diseases, as well as cardiovascular, neurological, pain management, and hormone therapy products. Laboratorio Chile also makes such consumer fare as sweetener Marco Sweet, nutritional supplement Esvit-C, and Freshmel antiseptic throat lozenges. The company markets its wares in over a dozen Latin American countries.

NexMed, Inc. was founded in 1987 and is based in San Diego, California. NexMed, Inc. is a pharmaceutical and medical technology company with a focus on developing and commercializing therapeutic products based on its delivery systems. The Company focuses its efforts on new and topical pharmaceutical products based on a penetration enhancement drug delivery technology known as NexACT, which may enable an active drug to be better absorbed through the skin. The NexACT transdermal drug delivery technology is designed to enhance the absorption of an active drug through the skin, overcoming the skin’s natural barrier properties, and enabling high concentrations of the active drug to rapidly penetrate the desired site of the skin or extremity. In December 2009, the Company closed its acquisition of Bio-Quant, Inc., a research organization for in vitro and in vivo contract drug discovery and pre-clinical development services.

BioVex Group has developed a virus-containing vaccine which works to prevent and combat certain types of cancer and chronic infectious diseases. The company's lead product, OncoVEX, makes use of an altered virus to attack solid tumor cells but leave healthy cells intact. OncoVEX has shown promise in treating metastatic melanoma and the company has plans to vex other cancers such as pancreatic and colo-rectal cancers. After a brief stint as a publicly-traded company, in 2007 BioVex was taken private by a group of investors led by health science-oriented Triathlon Medical Ventures.

ViroPharma Incorporated was founded in 1994 and is headquartered in Exton, Pennsylvania. ViroPharma Incorporated, a biopharmaceutical company, engages in the development and commercialization of products that address serious diseases with a focus on products used by physician specialists or in hospital settings in the United States and internationally. Its products include Vancocin HCl capsules for the treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile infection (CDI) and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains; and Cinryze for the prevention of hereditary angioedema attacks. The company's products in development include Maribavir, which is in Phase III clinical development stage for the prevention and treatment of cytomegalovirus disease; and non-toxigenic strains of C. difficile, which is in preclinical stage for the treatment and prevention of CDI. It licensed the third product development candidate, an intranasal formulation of pleconaril, to Schering-Plough for the treatment of picornavirus infections in the U.S. and Canada. It sells its products directly to wholesale drug distributors, and specialty pharmacies/specialty distributors. The company has strategic relationships with Eli Lilly and Company, GlaxoSmithKline, Schering-Plough Corporation, and Sanofi-Aventis.

Applied Molecular Evolution (AME) is part of the Lilly Biotechnology Center of San Diego. AME is a leader in applying directed molecular evolution to improve healthcare by discovering, optimizing and developing human biotherapeutics. Since its inception, AME’s principal focus has been on applying its proprietary AMEsystem™ technology platform to the full range of protein therapeutic candidates including antibodies, cytokines, hormones and enzymes to develop novel human biotherapeutic candidates.Since February 2004, AME has been a wholly-owned subsidiary of Eli Lilly and Company and is an integral part of Lilly’s research organization. Lilly, a leading innovation-driven corporation is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Lilly provides answers – through medicines and information – for some of the world’s most urgent medical needs.

Dako makes disease diagnosis a little more clear-cut. A leader in the area of pathology testing, Dako makes instrumentation systems, reagents, and software used by pathology laboratories to analyze human tissues for the presence of cancer. Its Automated Link line of pathology instruments include staining and visualization systems, chemical and antibody reagents, and Dako Link workflow management software. The company also makes reagents used in flow cytometry testing (which analyzes the cells in blood) and in clinical immunochemistry (which measures proteins in body fluids). The company was acquired by private equity fund EQT in 2007 and subsequently divested its flow cytometry instrumentation business.

Genzyme Diagnostics was founded in 1981. A division of Genzyme, it develops, manufactures, and distributes "in vitro" diagnostic products, including point-of-care tests. The division also produces the raw materials (such as enzymes and antibodies used in tests for diabetes, cholesterol, and pancreatitis) and chemical reagents used by other diagnostic test manufacturers to make their own diagnostic tests. The company's point-of-care products (tests administered at a patient's bedside) include tests for strep A, mononucleosis, and bacterial vaginitis; it also offers several different pregnancy tests.

Repros Therapeutics Inc. was founded in 1987 and is based in The Woodlands, Texas. Repros Therapeutics Inc., a development stage biopharmaceutical company, focuses on the development of oral small molecule drugs for the treatment of male and female reproductive disorders. Its lead drug includes Proellex, a selective blocker of the progesterone receptor, which is in Phase III clinical trials for use as a pre-surgical treatment for women with anemia due to excessive menstrual bleeding associated with uterine fibroids, or anemia associated with uterine fibroids; in Phase III clinical trials for the chronic treatment of symptoms associated with uterine fibroids; and in Phase II clinical trials for the chronic treatment of symptoms associated with endometriosis. The company's product candidates also comprise Androxal, a single isomer of clomiphene citrate, which is in Phase IIb clinical trials for the treatment of low testosterone levels in men, who want to improve or maintain their fertility and/or sperm number and function. In addition, it holds a patent portfolio of phentolamine-based product candidates, including VASOMAX for the treatment of male erectile dysfunction under the Z-Max brand name. The company was formerly known as Zonagen, Inc. and changed its name to Repros Therapeutics Inc. in May 2006 to reflect company's focus on therapeutics for reproductive disorders.

American Bio Medica Corporation develops, manufactures, and sells immunoassay diagnostic test kits for the point of collection testing (POCT) for drugs of abuse in North America, Europe, the Asia/Pacific Rim, Africa, and South America. Its products include Rapid Drug Screen, a POCT kit to detect the presence or absence of 2 to 10 drugs of abuse in a single urine specimen; Rapid One, which screens for the presence or absence of a single drug of abuse in a urine specimen; Rapid TEC that contains 1 or 2 drug testing strips to test for 2 to 5 drugs of abuse in a single urine specimen; RDS InCup, a POCT for 2 to 12 drugs of abuse that incorporate collection and testing of sample in a device; Rapid TOX, a drug screen that detects 2 to 10 drugs of abuse in a single urine specimen; and Rapid TOX Cup, a POCT for 2 to 14 drugs of abuse that incorporate collection and testing of sample in a single device.American Bio Medica Corporation company’s products also include OralStat, a POCT system to detect drugs of abuse in oral fluids; OralStat EX, an oral fluid POCT for point of collection testing and confirmation testing; and Rapid STAT, an oral fluid POCT. In addition, it offers Rapid Reader, a compact and portable device that captures a picture of the test results on an ABMC drug screen. Further, American Bio distributes various POCTs to detect the presence or absence of adulterants, alcohol, and nicotine; and provides bulk strip contract manufacturing services to non-affiliated POCT diagnostic companies. It offers products for employers, law enforcement, government, health care, laboratory, and education professionals to test for cocaine, THC, opiates, amphetamines, PCP, benzodiazepines, methamphetamines, barbiturates, tricyclic antidepressants, methadone, oxycodone, propoxyphene, and buprenorphine. The company was formerly known as American Micro Media, Inc and changed its name to American Bio Medica Corporation in September 1992. The company was founded in 1986 and is based in Kinderhook, New York.

The Mentholatum Company's best-known products, Mentholatum Deep Heating Rub, but they can probably find another of the company's bestsellers in their medicine cabinets -- Oxy Pads. The Mentholatum Company, a subsidiary of ROHTO Pharmaceutical, makes OTC products to relieve a variety of common ailments, including acne, cold sores, aches and pains, and chest congestion. In addition to the Oxy and Mentholatum brands, the firm sells its products under the WellPatch, Rohto, Fletcher's, Red Cross, Natural Ice, and Softlips monikers. ROHTO's Mentholatum companies have operations in more than a dozen countries and sells products in more than 150 countries.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.